This week on tHEORetically Speaking, we’re covering four major stories shaping the landscape across medtech, neurotech, drug development, and global pharma: Laborie buys Organon’s Jada system, NextSense raises a new round to launch EEG Smartbuds, Evotec and BMS hit an IND milestone, and Merck goes big with a $9.2B antiviral acquisition. A fast, focused roundup of the headlines you need to know. Subscribe for weekly drops!
All content for tHEORetically Speaking is the property of HealthEconomics.com and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This week on tHEORetically Speaking, we’re covering four major stories shaping the landscape across medtech, neurotech, drug development, and global pharma: Laborie buys Organon’s Jada system, NextSense raises a new round to launch EEG Smartbuds, Evotec and BMS hit an IND milestone, and Merck goes big with a $9.2B antiviral acquisition. A fast, focused roundup of the headlines you need to know. Subscribe for weekly drops!
Weekly News Roundup – Public Health Flashpoints, Pharma Innovation, and Pricing Battles
tHEORetically Speaking
5 minutes
1 month ago
Weekly News Roundup – Public Health Flashpoints, Pharma Innovation, and Pricing Battles
This week’s tHEORetically Speaking News Roundup covers the ACIP’s heated vaccine policy debates, growing state-level divides in COVID-19 vaccine access, and pharma’s race to develop multi-specific antibodies. We also explore the looming $32 billion revenue loss tied to expiring ACA subsidies and the latest legal battles over IRA drug pricing. Tune in for this concise recap of these pivotal industry updates!
tHEORetically Speaking
This week on tHEORetically Speaking, we’re covering four major stories shaping the landscape across medtech, neurotech, drug development, and global pharma: Laborie buys Organon’s Jada system, NextSense raises a new round to launch EEG Smartbuds, Evotec and BMS hit an IND milestone, and Merck goes big with a $9.2B antiviral acquisition. A fast, focused roundup of the headlines you need to know. Subscribe for weekly drops!
